Last reviewed · How we verify
Miconazole plus Hydrocortisone
Miconazole plus Hydrocortisone, marketed by Janssen Pharmaceutica, is a combination antifungal and corticosteroid product currently available in the market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Miconazole plus Hydrocortisone |
|---|---|
| Sponsor | Janssen Pharmaceutica |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Miconazole plus Hydrocortisone CI brief — competitive landscape report
- Miconazole plus Hydrocortisone updates RSS · CI watch RSS
- Janssen Pharmaceutica portfolio CI